Concepedia

Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium

Roel J.W. van Kampen, Bram Ramaekers, D.J.A. Lobbezoo, Maaike de Boer, M. Wouter Dercksen, F. Van den Berkmortel, Tineke J. Smilde, Agnès J. van de Wouw, Frank Peters, J.M.G. van Riel,

European Journal of Cancer · 2017 · 20 citations · 18 references

DOI

Concepts

References

18

Modeling Valuations for EuroQol Health States

Paul Dolan · Medical Care · 1997 · 4.6K citations

, , +16

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

Kathy D. Miller, Molin Wang, Julie R. Gralow et al. · New England Journal of Medicine · 2007 · 3.1K citations · Full text

, , +13

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Nicholas J. Robert, Véronique Dièras, John A. Glaspy et al. · Journal of Clinical Oncology · 2011 · 1.1K citations

, , +15

Economic burden of cancer across the European Union: a population-based cost analysis

Ramón Luengo-Fernández, José Leal, Alastair Gray et al. · The Lancet Oncology · 2013 · 1K citations

, , +16

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

David Miles, Arlene Chan, Luc Dirix et al. · Journal of Clinical Oncology · 2010 · 887 citations

, , +17